generation run 2026-05-03
71 min completedmodel pipeline-v5plan not recordedrun/e22060a8…Selection
Verification
- record
- seen / partial
- working
The model's own caveats
none raised on this run
Reproduce
- inputs
- 40 source keys (listed under Sources)
- plan
- not recorded — template version, prompt hash and git SHA are written from 2026-09 onward
- model
- pipeline-v5
- streams
- none — agent transcripts are persisted from 2026-09 onward
20 searches — query, source, results, what was kept and why
| # | source | query | seen | kept | rationale |
|---|---|---|---|---|---|
| 1 | PubMed | ephedrine cardiovascular stroke myocardial infarction adverse events | 7 | 6 | Key safety and toxicity data |
| 2 | PubMed | ephedrine athletics performance ergogenic doping sport | 6 | 2 | Performance-enhancement and doping context |
| 3 | PubChem | ephedrine | 1 | 1 | Primary chemical identity verification for the brief |
| 4 | PubMed | ephedrine pharmacology mechanism action adrenergic receptor | 10 | 4 | Directly relevant to pharmacology and mechanism of action |
| 5 | PubMed | ephedrine spinal anesthesia hypotension obstetric cesarean vasopressor | 10 | 4 | Clinical use data |
| 6 | PubMed | ephedrine urinary excretion half-life renal elimination urine pH | 1 | 1 | Pharmacokinetic data on renal excretion/pH dependence - applicable to ephedrine by close structural analogy |
| 7 | PubMed | ephedrine pharmacokinetics bioavailability half-life metabolism humans | 7 | 2 | Key pharmacokinetic data for humans |
| 8 | ClinicalTrials.gov | ephedrine | 15 | 2 | Active/recent clinical trials directly studying ephedrine |
| 9 | OpenAlex | ephedrine cardiovascular adverse events ephedra dietary supplement | 8 | 2 | Landmark papers on ephedrine safety |
| 10 | PubMed | ephedrine phenylephrine cesarean spinal anesthesia vasopressor neonatal | 8 | 4 | Clinical data on vasopressor use in obstetrics |
| 11 | PubMed | ephedrine Ephedra sinica traditional Chinese medicine ma huang history | 3 | 1 | Authoritative history of ephedrine from isolation to banning |
| 12 | StatPearls (NCBI Bookshelf) | ephedrine pharmacokinetics clinical pharmacology | 1 | 1 | Authoritative clinical reference with pharmacokinetic data |
| 13 | Web | ephedrine FDA dietary supplement ban 2004 | 10 | 1 | Confirms regulatory history |
| 14 | Web | ephedrine pharmacokinetics half-life bioavailability | 10 | 2 | Confirms key PK parameters |
| 15 | Web | ephedrine legal status UK Australia scheduling | 10 | 2 | Legal status data not available via academic APIs |
| 16 | ClinicalTrials.gov · absence | ephedrine obesity weight loss | 0 | — | Confirms absence of active weight loss trials (consistent with 2004 ban) |
| 17 | Web | Nagai Nagayoshi 1885 ephedrine isolation | 10 | 1 | Primary historical source |
| 18 | INCHEM IPCS PIM 209 | ephedrine toxicity pharmacokinetics overdose | 1 | 1 | WHO/IPCS authoritative toxicology reference |
| 19 | PubMed | ephedrine psychosis psychiatric adverse effects | 8 | 4 | Documents psychiatric and dependence complications |
| 20 | PubMed | ephedrine norephedrine metabolite N-demethylation urinary excretion | 2 | 2 | Primary metabolism data in humans |
79 claims by section — every cited sentence, checked against its source
safety27 · 23 ok
Ten deaths and 13 permanent disabilities were documented, representing 26% of cases judged probable or possibly related.supported
10 deaths, 13 permanent disabilities. nejm200012213432502
Shekelle and colleagues' meta-analysis of 50 trials demonstrated a 2.2–3.6-fold increase in odds of psychiatric, autonomic, or gastrointestinal symptoms and heart palpitations versus placebo.partially supported
Meta-analysis of 52 controlled trials. 2.2-3.6x increased odds of psychiatric, autonomic, GI symptoms and palpitations. jama.289.12.1537
Acute myocardial infarction: Kranjec and colleagues reported intracoronary thrombus in the left anterior descending artery in a young athlete with ephedrine abuse. Samenuk and colleagues documented a case series of cardiovascular adverse events temporally associated with ma huang supplements.supported
Case report of acute MI in young athlete with ephedrine abuse. Intracoronary thrombus in LAD resolved with aspiration. 0003319707310280
Acute myocardial infarction: Kranjec and colleagues reported intracoronary thrombus in the left anterior descending artery in a young athlete with ephedrine abuse. Samenuk and colleagues documented a case series of cardiovascular adverse events temporally associated with ma huang supplements.supported
Evaluation of cardiovascular toxic effects of dietary supplements containing ma huang (ephedra). pmid:11795249
Cardiomyopathy: Clark and Schofield reported dilated cardiomyopathy with combined ephedra/GHB/anabolic steroid use. Martinez-Quintana and colleagues documented biventricular dysfunction and myocardial necrosis from chronic ephedrine abuse, with partial left ventricular recovery after five years of abstinence.supported
Case report of dilated cardiomyopathy and acute hepatitis in bodybuilder using ephedra, GHB, and anabolic steroids. pmid:15899737
Cardiomyopathy: Clark and Schofield reported dilated cardiomyopathy with combined ephedra/GHB/anabolic steroid use. Martinez-Quintana and colleagues documented biventricular dysfunction and myocardial necrosis from chronic ephedrine abuse, with partial left ventricular recovery after five years of abstinence.supported
Case report: dilated cardiomyopathy and myocardial necrosis from chronic ephedrine abuse. Partial LV recovery after 5 years abstinence. pmid:20300711
An important counterpoint: Hallas and colleagues' registry-based case-crossover study of 257,364 users of prescribed ephedrine/caffeine in Denmark found no significantly increased risk of death, myocardial infarction, or stroke (adjusted OR 0.95, 95% CI 0.79–1.16)supported
Registry study of 257,364 users. No substantially increased risk of death, MI, or stroke with prescribed ephedrine/caffeine (OR 0.95, 95% CI 0.79-1.16). kwn191
In obstetric anesthesia, ephedrine use for post-spinal hypotension is associated with lower neonatal umbilical artery pH values versus phenylephrinesupported
phenylephrine associated with higher neonatal umbilical arterial pH. pmid:11916798
In obstetric anesthesia, ephedrine use for post-spinal hypotension is associated with lower neonatal umbilical artery pH values versus phenylephrinesupported
phenylephrine now considered vasopressor of choice in obstetrics due to improved neonatal acid-base status vs ephedrine. j.bpa.2017.01.001
Psychosis: Substance-induced psychotic disorder has been reported in multiple case reports and case series. Tang and colleagues found substance-induced psychotic disorder in 67% of cough mixture abusers (formulations containing ephedrine) referred to substance abuse clinics in Hong Kong.supported
Case report of acute mania with psychosis in 21-year-old woman using ma-huang supplements. pmid:12627938
Psychosis: Substance-induced psychotic disorder has been reported in multiple case reports and case series. Tang and colleagues found substance-induced psychotic disorder in 67% of cough mixture abusers (formulations containing ephedrine) referred to substance abuse clinics in Hong Kong.supported
Psychiatric complications including psychosis associated with ma-huang (ephedra) use. pmid:10665269
Psychosis: Substance-induced psychotic disorder has been reported in multiple case reports and case series. Tang and colleagues found substance-induced psychotic disorder in 67% of cough mixture abusers (formulations containing ephedrine) referred to substance abuse clinics in Hong Kong.supported
substance-induced psychotic disorder in 67%. pmid:23271584
Psychosis: Substance-induced psychotic disorder has been reported in multiple case reports and case series. Tang and colleagues found substance-induced psychotic disorder in 67% of cough mixture abusers (formulations containing ephedrine) referred to substance abuse clinics in Hong Kong.supported
substance-induced psychotic disorder in 67%. pmid:23271584
Mania: Case reports document manic episodes associated with ma huang use.supported
Case report of acute mania with psychosis in 21-year-old woman using ma-huang supplements. pmid:12627938
Dose-dependent CNS excitation: At therapeutic-to-supratherapeutic doses, anxiety, agitation, and tremor are common. At higher doses or with chronic use, mental confusion, hallucinations, and paranoid psychosis may emerge.partially supported
Increased CNS stimulation and anxiety. Dose range 37.5-75 mg oral. pmid:7862849
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — not_supportednot supportedworking →
Pickup and colleagues confirmed in asthmatic patients that pharmacokinetic parameters are unchanged during chronic dosingsupported
No significant intra-subject changes in kinetic parameters after chronic dosing. pmid:973934
Sever and colleagues ruled out inhibitory metabolite formation by demonstrating absence of phenolic metabolitessupported
No phenolic metabolites. Tolerance not related to metabolism. pmid:786688
Chait found a 17% choice rate in non-dependent adults, indicating low reinforcing potential relative to classical stimulantssupported
ephedrine chosen 17% of occasions. pmid:7862849
However, Miller documented frank addiction to ephedra preparations, and cough mixture abuse data from Hong Kong demonstrate that chronic use of ephedrine-containing formulations can produce substance use disorder with associated psychosis.supported
Letter documenting addiction potential of ephedra preparations. pmid:16263877
However, Miller documented frank addiction to ephedra preparations, and cough mixture abuse data from Hong Kong demonstrate that chronic use of ephedrine-containing formulations can produce substance use disorder with associated psychosis.supported
ephedrine found in 57% urine samples of cough mixture abusers; substance-induced psychotic disorder in 67%. pmid:23271584
Cross-tolerance: Dambisya and colleagues demonstrated in mice that chronic ephedrine pretreatment enhanced opiate tolerance and suppressed opiate withdrawal signs, suggesting shared neuroadaptive mechanismssupported
Chronic ephedrine pretreatment attenuated morphine antinociception; enhanced opiate tolerance; suppressed withdrawal signs when given during expression phase. pmid:1875772
Haller and colleagues demonstrated enhanced hemodynamic and metabolic responses with the combination, and the Shekelle meta-analysis documented 2.2–3.6 times greater adverse event rates for ephedrine/caffeine combinations versus either agent alone.supported
Pharmacologic interaction between ephedrine and caffeine; clinically significant synergy explaining toxicities. pmid:15060505
Haller and colleagues demonstrated enhanced hemodynamic and metabolic responses with the combination, and the Shekelle meta-analysis documented 2.2–3.6 times greater adverse event rates for ephedrine/caffeine combinations versus either agent alone.partially supported
2.2-3.6x increased odds of psychiatric, autonomic, GI symptoms and palpitations. jama.289.12.1537
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
pharmacology12 · 8 ok
Separately, ephedrine-induced nitric oxide (NO) production is secondary to β₂ receptor stimulation, with NO modulating the net vascular response.supported
NO modulates vascular response to ephedrine; NO production from ephedrine is secondary to beta2-receptor stimulation. pmid:14608414
Jia and colleagues demonstrated in PC12 cells that ephedrine induces thioredoxin-1 expression via a β-adrenergic receptor → cyclic AMP → protein kinase A → DARPP-32 → CREB phosphorylation signaling cascadesupported
Ephedrine induces Trx-1 through β-AR/cAMP/PKA/DARPP-32 pathway; PKA-mediated CREB phosphorylation demonstrated in PC12 cells. j.cellsig.2013.02.007
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
In direct contrast, Liles and colleagues found that ephedrine pressor responses in rats were not attenuated by NET blockade (desipramine) or catecholamine depletion with reserpine/α-methyl-p-tyrosine, arguing for predominantly direct α-adrenergic receptor mediation. This distinguished ephedrine from amphetamine and tyramine, whose responses were abolished by the same treatments.supported
I.v. ephedrine pressor responses in rats not attenuated by norepinephrine reuptake blocker or catecholamine depletion, supporting direct alpha-receptor mediation. pmid:16002460
Docherty classifies it as a monoaminomimetic agent acting on both adrenergic and dopaminergic systems.supported
monoaminomimetic mechanism. bjp.2008.124
Sever and colleagues characterized three urinary metabolic pathways in humans:supported
Unchanged drug 53-74%; N-demethylation 8-20%; oxidative deamination 4-13%. pmid:786688
No phenolic metabolites are detected, distinguishing ephedrine metabolism from catecholamine pathwayssupported
No phenolic metabolites. pmid:786688
Claim in pharmacology — inconclusiveinconclusiveworking →
Acidic urine greatly enhances renal clearance, while alkaline urine prolongs half-life dramatically — data from the structural analog pseudoephedrine showed half-life extending from approximately 2 hours to 21 hours with urine alkalinizationsupported
half-life ranges from 1.9 to 21h with alkaline vs acidic urine. pmid:7438686
Total urinary recovery at 48 hours reaches 97% of the administered dose, with 53–74% excreted as unchanged drug.supported
97% excreted in urine within 48h. Unchanged drug 53-74%. pmid:786688
summary8 · 7 ok
Isolated from Ephedra sinica (ma huang) by Nagai Nagayoshi in 1885, ephedrine was the first orally bioavailable sympathomimetic to achieve widespread clinical use — replacing injectable adrenaline for asthma by the 1920ssupported
Ephedrine isolated by Nagai 1885; rediscovered by Chen and Schmidt early 1920s. Used for asthma. jrcpe.2011.116
Claim in summary — inconclusiveinconclusiveworking →
No quantitative binding affinity (Ki) data have been published for individual receptor subtypes, and the relative contribution of direct versus indirect action remains debatedsupported
l-ephedrine pressor response is entirely attributable to norepinephrine release in vivo, though some direct adrenoceptor activation detectable at tissue level. 01.ane.0000092917.96558.3c
No quantitative binding affinity (Ki) data have been published for individual receptor subtypes, and the relative contribution of direct versus indirect action remains debatedsupported
I.v. ephedrine pressor responses in rats not attenuated by norepinephrine reuptake blocker or catecholamine depletion, supporting direct alpha-receptor mediation. pmid:16002460
Subjectively, ephedrine produces stimulation, wakefulness, appetite suppression, and dose-dependent anxiety, with mild euphoria on standardized mood scalessupported
Increased 'high' and MBG euphoria ratings. Increased CNS stimulation and anxiety. pmid:7862849
Cardiovascular toxicity is the principal safety concern: fatal blood concentrations as low as 3.49 mg/L have been documented, and meta-analysis of 50 trials showed a 2.2–3.6-fold increase in adverse psychiatric, autonomic, and gastrointestinal events versus placebopartially supported
Meta-analysis of 52 controlled trials. 2.2-3.6x increased odds of psychiatric, autonomic, GI symptoms and palpitations. jama.289.12.1537
Tachyphylaxis develops rapidly through pharmacodynamic mechanisms — presynaptic norepinephrine depletion and receptor downregulation — with no change in pharmacokinetic parameters during chronic dosingsupported
No significant intra-subject changes in kinetic parameters after chronic dosing. Tolerance not disposition-related. pmid:973934
Reinforcing potential is low (17% choice rate in controlled study), though case reports document frank addictionsupported
Letter documenting addiction potential of ephedra preparations. pmid:16263877
clinical-evidence7 · 6 ok
Astrup and colleagues conducted a randomized controlled trial comparing ephedrine (20 mg TID), caffeine (200 mg TID), the combination, and placebo in obese subjects on an energy-restricted dietsupported
180 obese patients, 24 weeks. Ephedrine/caffeine combination (20/200 mg TID). Ephedrine alone had no significant effect over placebo. pmid:1318281
In a separate trial, ephedrine monotherapy at 150 mg/day produced statistically significant weight loss in low-energy-adapted obese women.supported
l-ephedrine HCl 50 mg TID significantly greater weight loss (2.41 kg) vs placebo (0.64 kg) at 2 months. pmid:3301709
Shekelle and colleagues conducted a comprehensive meta-analysis of 50 trials examining ephedrine and ephedra for weight loss and athletic performancepartially supported
Meta-analysis of 52 controlled trials. jama.289.12.1537
Claim in clinical-evidence — inconclusiveinconclusiveworking →
Lee and colleagues published a quantitative systematic review of randomized controlled trials comparing ephedrine to phenylephrine for hypotension management during spinal anesthesia for cesarean delivery, establishing phenylephrine's superiority for neonatal umbilical artery pH outcomes.supported
Meta-analysis of 7 RCTs. No difference in hypotension management, but phenylephrine associated with higher neonatal umbilical arterial pH. pmid:11916798
Mohta and colleagues conducted a randomized double-blind trial comparing bolus phenylephrine and ephedrine in women with pre-eclampsia undergoing cesarean section, providing evidence on neonatal outcomes in this high-risk population.supported
80 pre-eclamptic women. Phenylephrine 50 mcg vs ephedrine 4 mg boluses. Similar efficacy; higher heart rate with ephedrine. Similar umbilical artery pH. anae.14268
Contemporary network meta-analyses rank vasopressors for cesarean delivery as norepinephrine > phenylephrine > ephedrine.supported
Norepinephrine ranked highest; phenylephrine second; ephedrine third for post-spinal hypotension in cesarean delivery. cureus.101603
history6 · 4 ok
Claim in history — inconclusiveinconclusiveworking →
In 1885, Japanese organic chemist Nagai Nagayoshi (1844–1929) isolated and characterized ephedrine as a pure alkaloid from Ephedra sinica at Tokyo Imperial University, applying Western analytical chemistry to a traditional herbal remedysupported
Ephedrine isolated by Nagai 1885. jrcpe.2011.116
Claim in history — inconclusiveinconclusiveworking →
In 2000, Haller and Benowitz published a landmark review in the New England Journal of Medicine analyzing 140 FDA adverse event reports associated with ephedra-containing supplements, documenting 10 deaths and 13 cases of permanent disabilitysupported
Review of 140 FDA adverse event reports. 10 deaths, 13 permanent disabilities. nejm200012213432502
On April 12, 2004, the FDA issued a final rule declaring dietary supplements containing ephedrine alkaloids adulterated under the Dietary Supplement Health and Education Act, classifying them as presenting an "unreasonable risk of illness or injury"supported
FDA final rule effective April 12, 2004 banning dietary supplements containing ephedrine alkaloids as presenting unreasonable risk of illness or injury. pmid:14968803
Contemporary systematic reviews consistently rank norepinephrine and phenylephrine as superior to ephedrine for prevention and treatment of post-spinal hypotension in cesarean delivery, and ephedrine's clinical role continues to narrowsupported
phenylephrine now considered vasopressor of choice in obstetrics due to improved neonatal acid-base status vs ephedrine. j.bpa.2017.01.001
comparative-pharmacology5 · 4 ok
Ephedrine and pseudoephedrine are diastereomers — (1R,2S) and (1S,2R) configurations respectively — with meaningfully different pharmacological profilessupported
l-ephedrine pressor response entirely attributable to norepinephrine release in vivo. d-Pseudoephedrine entirely indirect. 01.ane.0000092917.96558.3c
Pseudoephedrine's pH-dependent elimination follows the same pattern as ephedrine, with half-life extending from approximately 2 hours (acidic urine) to 21 hours (alkaline urine).supported
half-life ranges from 1.9 to 21h with alkaline vs acidic urine. pmid:7438686
Claim in comparative-pharmacology — inconclusiveinconclusiveworking →
Reinforcing potential: Ephedrine shows low reinforcing potential (17% choice rate) versus amphetamine's well-documented high abuse liabilitysupported
ephedrine chosen 17% of occasions. pmid:7862849
Mechanistic distinction: Liles and colleagues demonstrated that amphetamine pressor responses are abolished by NET blockade and catecholamine depletion, while ephedrine responses are not — suggesting ephedrine has a proportionally greater direct receptor componentsupported
I.v. ephedrine pressor responses in rats not attenuated by norepinephrine reuptake blocker or catecholamine depletion, supporting direct alpha-receptor mediation. pmid:16002460
neuroscience4 · 2 ok
Claim in neuroscience — inconclusiveinconclusiveworking →
The β-AR → cAMP → PKA → DARPP-32 → CREB pathway identified in PC12 cells provides a molecular link between adrenergic receptor activation and gene expression changes (thioredoxin-1 induction)supported
Ephedrine induces Trx-1 through β-AR/cAMP/PKA/DARPP-32 pathway; PKA-mediated CREB phosphorylation demonstrated in PC12 cells. j.cellsig.2013.02.007
Claim in neuroscience — not_supportednot supportedworking →
Does chronic ephedrine exposure produce lasting catecholamine system changes? Case reports of addiction and animal data showing enhanced opiate tolerance after chronic ephedrine pretreatment suggest possible long-term neuroadaptation, but systematic characterization is absent.supported
Letter documenting addiction potential of ephedra preparations. pmid:16263877
receptor-pharmacology4 · 2 ok
Claim in receptor-pharmacology — inconclusiveinconclusiveworking →
Claim in receptor-pharmacology — inconclusiveinconclusiveworking →
β₂ receptors: Mediate bronchodilation (the historical therapeutic application) and vasodilation in skeletal muscle vasculature. Dabisch and colleagues demonstrated that ephedrine-induced nitric oxide production is secondary to β₂ stimulation.supported
NO modulates vascular response to ephedrine; NO production from ephedrine is secondary to beta2-receptor stimulation. pmid:14608414
The indirect component — NET inhibition and vesicular NE displacement — dominates the systemic pharmacological profile under most conditions, though the direct component may become proportionally more important as presynaptic NE stores deplete during tachyphylaxissupported
l-ephedrine pressor response is entirely attributable to norepinephrine release in vivo, though some direct adrenoceptor activation detectable at tissue level. 01.ane.0000092917.96558.3c
chemistry3 · 1 ok
Claim in chemistry — inconclusiveinconclusiveworking →
Claim in chemistry — inconclusiveinconclusiveworking →
Stereochemistry influences both pharmacodynamics and pharmacokinetics: D(-)-ephedrine is metabolized approximately three times faster than L(+)-ephedrine via oxidative deamination to benzoic acid in rabbit models, and the two diastereomers (ephedrine vs pseudoephedrine) show distinct in vivo pressor response profiles in anesthetized rats.supported
l-ephedrine pressor response entirely attributable to norepinephrine release in vivo. d-Pseudoephedrine entirely indirect. 01.ane.0000092917.96558.3c
pharmacokinetic-detail3 · 3 ok
The three identified metabolic pathways — excretion of unchanged drug (53–74%), N-demethylation to norephedrine (8–20%), and oxidative deamination to benzoic acid (4–13%) — are not CYP-mediatedsupported
Unchanged drug 53-74%; N-demethylation 8-20%; oxidative deamination 4-13%. No phenolic metabolites. pmid:786688
Data from the structural analog pseudoephedrine demonstrated half-life extending from approximately 2 hours in acidic urine to 21 hours in alkaline urinesupported
half-life ranges from 1.9 to 21h with alkaline vs acidic urine. pmid:7438686
Pickup and colleagues demonstrated in asthmatic patients receiving chronic ephedrine therapy that pharmacokinetic parameters (absorption rate, half-life, clearance) do not change with repeated dosingsupported
No significant intra-subject changes in kinetic parameters after chronic dosing. Tolerance not disposition-related. pmid:973934